Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNC-102 in Tourette Syndrome
NCT02217007Phase 2Withdrawn
- Sponsor
- Synchroneuron Inc.
- Start
- Apr 2015
- Primary completion
- Jan 2016
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of SNC-102 in Tourette syndrome (TS), sponsored by Synchroneuron Inc.. Planned start Apr 2015; status: withdrawn.
02
Drugs
SNC-102
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT02217007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02217007.